Daily close, T-120 (2/25/25) through T+5. Run-up high $112.89 on 8/11/25, low $64.81 on 4/16/25 (T-120 to T-1). FDA decision 8/12/25. Historical price action, not a forecast.
Positioning before the decision
On Jul 29, 2025, 14 days before the decision date, at-the-money options priced a move of ±11.2% through Aug 15, 2025 (the first listed expiry after the decision; ATM implied volatility 65%). The stock closed +8.1% at the first close across the decision and +12.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was BRINSUPRI (Brensocatib) - (ASPEN) approved by the FDA?
Yes. The FDA approved the application for BRINSUPRI (Brensocatib) - (ASPEN) on August 12, 2025. The primary source is linked on this page.
What was BRINSUPRI (Brensocatib) - (ASPEN) under FDA review for?
The application covered Non-Cystic Fibrosis Bronchiectasis (NCFBE). The FDA approved the application on August 12, 2025.
How did INSM stock react to the FDA decision?
On the decision day INSM moved +8.1%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.